GEN Exclusives

More »

GEN News Highlights

More »
Jul 30, 2007

Vivus Eligible to Receive Milestone Payment of $140M from KV Pharmaceutical

  • Vivus received FDA approval for the marketing of Evamist™, a metered dose transdermal estradiol spray for the treatment of moderate-to-severe vasomotor symptoms due to menopause. Evamist is the first estradiol transdermal spray approved by the FDA, reports the company.

    Vivus previously announced an agreement with KV Pharmaceutical for the grant of a sublicense of exclusive rights and sale of assets related to Evamist on March 30, 2007. At the closing of the transaction in May, Vivus received a cash payment of $10 million. Under the terms of the agreement, Vivus is also eligible to receive an additional $140 million cash payment upon the approval of the NDA for Evamist. The payment is expected five days after the transfer of the NDA to KV. Vivus is expected to transfer and assign the NDA to KV by August 3, 2007.

    In the future, Vivus may also receive certain one-time milestone payments of up to $30 million based on net annual sales of Evamist.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »